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T

he drug & pharmaceutical industry play a vital role in the health care of any
country. Rapid growth of this industry requires further attention because even after
64 years of independence, India, with around 15 % of the world population,
accounts for less than 2 % of the drug production in the world. Annual per capita
consumption of medicine in India is less than 2% of that in Japan. Health care expense in
India is a dismal 0.8 % of GDP compared with 12.4 % in U.S.A. 6.5% in Japan and 6.2 %
in the U.K, despite higher incidence of disease and malnutrition. The poverty and disease in
India on one hand calls for higher standard of healthcare and pharmaceuticals production
and on the other, stultifies the growth of industry due to poor affordability of an average
Indian. The drug and pharmaceutical industry has, therefore, encountered a tough situation
which most industry have always found it difficult to provide abundant quantity of quality
products at low prices.
India has undertaken a major economic reform program since 1991. By virtue of this
program, intensive changes have been made in the industrial policy of the Indian
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government relaxation of licensing rules, reduction in tariff rates, removal of restrictions on
import etc. are among those which have been initiated in the early stages. The policy
reforms had the objectives to make Indian industries as well as the entire economy more
efficient, technologically up-to-date and competitive. This was done with the expectation
that efficiency improvement, technological up-gradation and competitiveness would ensure
Indian industry to achieve rapid growth.
The Indian pharmaceutical sector is likely to witness major changes as a result of
liberalization and pressure from GATT (General Agreement on Trade and Tariff) and WTO
(World Trade Organization). Price controls are gradually being dismantled with less than
50% of the drugs coming under the purview of DPCO. This number is likely to decrease
further. In addition, as a signatory to WTO by 2005, India will be required to follow the
same product patent laws governing the west. MNCs (Multinational Companies) in the past
have been constrained in launching new products because of strict patents enforcement law
governing their home countries. They are now keenly awaiting the protection of product
patent in 2005, which will provide greater freedom to introduce new advanced international
portfolio products. Indian pharmaceutical companies on the other hands are likely to suffer
as a result of patent protection. It will become increasingly difficult for them to introduce
new product without investing in basic research. Intensive research requires large
investment that can only be recovered by spreading costs over a greater volume, thereby
reducing average costs. However, because of high industry fragmentation and a lack of
research, few domestic companies are able to reap the benefit of scale. Drug manufacturers
are currently the most aggressive overseas investors of all Indian industries. They are
pursuing foreign acquisitions due to their need to: improved global competitiveness, move
up the value chain, create and enter new markets, increase their product offering, acquire
assets(including research and contract manufacturing firms, in order to further boost their
outsourcing capabilities) and new products, consolidate their market shares, and
compensate for continued sluggishness in their home market.
In view of greater openness in the Indian economy due to trade liberalization, the private
sector can build and expand capacity without much regulation. There had been an
investment boom in the manufacturing sector in the first half of 1990s (Uchikawa, 2001).
The advocates of liberalization believe that these policy reforms will improve industrial
growth and performance significantly while critics argue that total withdrawal of
restrictions on several matters will have a negative effect on future growth and performance
of the industry.
As a part and parcel of self-appraisal, each and every industry is constantly engaged in the
search for tools for assessing its own current performance. This performance can be judged
suitably by comparing it with the various targets, past achievements and operative capacity.
Business decision making and policy formulation mostly depend on economic indicators. In
a capital scarce economy like India, manufacturing capacity utilization is a key indicator of
economic performance which not only determines how much more output can be obtained
by fuller utilization of existing capacity but also defines the required expansion of capacity
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for a targeted output and also explains changes in investment, inflation, level of resource
utilization etc. Higher unutilized capacity implies slower growth rates. Therefore the
estimation of capacity output and its utilization will be very useful to evaluate the variations
in the performance of an industry over a period of time.
Against this backdrop, this paper attempts to measure capacity utilization of the Indian
pharmaceutical industry econometrically and analyze its trend over a period of 29 yearsfrom 1979-80 to2007-08 .The article also assesses the impact of liberalization on capacity
utilization. Another objective of this paper is to assess the influence of various explanatory
industrial characteristics on capacity utilization in a significant manner during the reform
period.
This study is conducted for the aggregates of an industry where capacity utilization has
been taken as a yard stick in measuring performance assuming that all the firms in an
industry behave alike and, therefore, industry level characteristics could be attributable to
all the firms operating in that industry. It is not claimed that capacity utilization is the only
yard stick for measuring the performance of an industry where there exist profitability and
productivity variables for evaluating industrial performance.
This paper is divided into the following sections: Section II depicts brief overview of
pharmaceutical industry and conceptual issues related to capacity. Section III provides data
base and methodology. Section IV estimates capacity and its utilization and interprets the
results and Section V assesses and analyzes the impact of liberalization on capacity
utilization and section VI analyzes the impact of various factors that influences capacity
utilization. Section VII presents summary and conclusions.

Brief overview of Pharmaceutical Industry
The annual turnover of the Indian pharmaceutical industry is estimated to be about US $ 17
billion (over Rs. 68,000 crore) during the year 2006-07. The share of export of drugs,
pharmaceuticals and fine chemicals is more than Rs. 24,000 crore (around US $ 6
Billion).This segment of Industry has shown tremendous progress in terms of infrastructure
development, technology base and wide range of products. The industry now produces bulk
drugs belonging to all major therapeutic groups requiring complicated manufacturing
processes and has also developed excellent GMP (Good Manufacturing Practices)
compliant facilities for the production of different dosage forms. The strength of the
industry is in developing cost effective technologies in the shortest possible time for drug
intermediates and bulk activities without compromising on quality. This is realized through
the country's strengths in organic chemicals' synthesis and process engineering.
The Indian pharmaceutical industry has come a long way from being almost non-existent in
the 1970s to being one of the largest and most advanced pharmaceutical industries in the
world. The domestic pharmaceutical output has increased at a CAGR (Compound annual
growth rate) of 13.4%.Currently, the Indian pharmaceutical industry is valued at $8 billion
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(approx).Globally, the industry ranks 4th in terms of volume and 13th in terms of value. It
provides employment to millions and ensures that essential drugs are available to the vast
population of India at affordable prices. Indian pharmaceutical industry has attained wide
ranging capabilities in the complex field of drug manufacture and technology developed
through a range of governmental incentives and the industry has been declared a knowledge
based industry. This Industry is a highly organized sector and is extremely fragmented with
severe price competitions and governmental price control. The major players in the Industry
are Ranbaxy, Dr. Reddy’s Laboratories, Cipla, Sun Pharmaceutical Industries, Lupin Lab,
Glaxo Smith Kline Pharmaceutical, Cadila Healthcare, Aventis etc.
India has the highest number of manufacturing plants approved by US FDA, which is next
only to that in the US. More than 85% of the formulations produced in the country are sold
in the domestic market. Over 60% of India's bulk drug production is exported. India holds
the lion's share of the world's contract research business, as activity in the pharmaceutical
market continues to explode, over 15 prominent contract research organizations (CROs) are
now operating in India attracted by her ability to offer efficient R&D on a low- cost basis.
Thirty five percent of business is in the field of new drug discovery and the rest 65 percent
of business is in the clinical trials arena. India offers a huge cost advantage in the clinical
trials domain compared to Western countries. India got a major boost with the signing of
Trade Related Intellectual Property Rights (TRIPS) under the General Agreement on Tariffs
and Trade (GATT) in January 2005 with which it began recognizing global patents. The
acceptance of patent laws and the rise of Contract Research and Manufacturing Sourcing
(CRAMS) have led to the diversification of revenue streams, enabling the Indian
pharmaceutical industry to experience high market growth.
India is today recognized as one of the leading global players in pharmaceuticals. Europe
accounts for the highest share of over 23% of Indian pharma exports followed by North
America and Asia. Exports to the USA have crossed the land mark figure of US $1 billion
during 2006-07. Internationally recognized as amongst the lowest-cost-producers of drugs,
India holds fourth position in terms of volume and thirteenth position in terms of value of
production in pharmaceuticals. It is estimated that by the year 2010, the Indian
pharmaceutical industry has the potential to achieve over Rs.1,00,000 crore production of
formulations and bulk drugs. Exports constitute a substantial part of the total production of
pharmaceuticals in India. The formulations contribute nearly 55% of the total exports and
the rest 45% comes from bulk drugs. Pharmaceutical exports clocked $7.2 billion in 200708, accounting for six per cent of the country’s total exports. Indian companies export drugs
to over 200 countries, but the top 25 markets, which include the US, Germany, Russia,
China and a few European and African countries, account for about half of the total. Indian
drug makers exported medicines worth Rs 31,608 crore during April 2008-January 2009
and exports shot up 30.7% as compared to last year due to a weak Indian currency and
increased demand for low-cost generic medicines. US is the largest importer of drugs
followed by Russia and Germany. Pharmaceutical industry accounts for about 2.91% of
total FDI into the country.
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Concept of Capacity
The concept of capacity has played an important role in economic analysis. Unlike many
well-defined concepts, capacity has been subjected to alternative definition and
misconceptions. The economists’ definition differs from the engineers’ idea of capacity
since what is technically possible may not be economically desirable. Simply, capacity
output is defined as the maximum feasible level of output of the firm. An economically
more meaningful definition of capacity output originated by Cassel (1937) is the level of
production where the firms long run average cost curve reaches a minimum. As we consider
the long run average cost, no input is held fixed. For a firm with the typical ‘U’ shaped
average cost curve, at this capacity level of output, economies of scale have been exhausted
but diseconomies have not set in. The physical limit defines the capacity of one or more
quasi-fixed inputs. Klein defined capacity as the maximum sustainable level of output an
industry can attain within a very short time, when not constrained by the demand for
product and the industry is operating its existing stock of capital at its customary level of
intensity. Klein (1960) argued that long run average cost curve may not have a minimum
and proposed the output level where the short run average cost curve is tangent to the long
run average cost curve as an alternative measure of capacity output. This is also the
approach adopted by Berndt and Morrison (1981). If technology exhibits constant return to
scale, long run average cost curve is horizontal and the capacity level output is not defined.
In this case, at the minimum point, the short run average cost curve is tangent to the long
run average cost curve. This helps to determine the economic capacity output in the short
run.
We prefer choice theoretic model 1 because it is firmly based in the behavioral concept of
economic theory. The choice theoretic approach defines capacity output as the long run
desired level of output given capital stock and input prices. The difference between
engineering and economic capacity can be termed as intended excess capacity and that
between economic capacity and actual output as unintended excess capacity.

III. Data base and methodology:
1

Cassel (1937) first suggests that a firm’s capacity output is the minimum of the long run average cost
curve. Klein (1960) and Friedman (1963) suggest capacity output as that output level at which long run
and short run average cost curves are tangent. Economic capacity is a short run concept. The fixed nature
of some inputs like capital characterizes short run. For any amount of fixed input like capital, the output
which can be obtained with the minimum long run cost method is capacity output which will require a
higher cost method of production and therefore short run average cost of output is above the long run
average cost curve except at the capacity output level. In the short run, higher cost methods are required
to obtain additional output since only variable inputs may be increased. Therefore, a firm with fixed
capital may choose to operate in the short run at a level of output that differs from the long run desired
level and variation in CU is viewed as a short run phenomenon due to quasi-fixity of capital.
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This paper covers a period of 29 years from 1979 – 80 to 2007 – 08. The entire period is
divided into two phases as pre- reform period (1979 – 80 to 1990 – 91) and post- reform
period (1991- 92 to 2007 – 08).
Viewing variations in capacity utilization as a short-run phenomenon caused by the quasifixed nature of capital, an econometrically tractable short-run variable-cost function which
assumes capital as a quasi-fixed input has been used to estimate capacity utilization.
Econometric Specification:
Considering a single output and three input framework (K, L, E) in estimating capacity
utilization where K, L and E are the capital, labor and energy inputs respectively, we
assume that firms produce output within the technological constraint of a well behaved 2
production function.
Y = f (K, L, E) where K, L and E are capital, labor and energy respectively. Since
capacity output is a short-run notion, the basic concept behind it is that firm faces short-run
constraints like stock of capital .Firms operate at full capacity where their existing capital
stock is at long-run optimal level. Capacity output is that level of output which would make
existing short-run capital stock optimal.
Rate of capacity utilization is given as
CU = Y/Y* ……… (1)
Y is actual output and Y* is capacity output. Our model assumes that capacity
utilization is a function of input prices, output and quasi-fixed capital .
Therefore, in association with variable profit function, there exists variable cost function
which can be expressed as
VC = f (PL, PE, K, Y)……. (2)
PL and PE are the price of labor and price of energy respectively and PK is the rental price of
capital.

Short run total cost (STC) function is expressed as
STC = f (PL, PE, K, Y) + PK.. K…………….(3)

PK is the rental price of Capital.
2

A production function is considered to be well-behaved if it has positive marginal product for each input
and it is quasi concave and also satisfies the conditions of monotonocity. Quasi-concavity required that
the bordered Hessian matrix of first and second partial derivatives of the production function be negative
semi definite.
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Variable cost equation 3 which is variant of general quadratic form for (2) that provide a
closed form expression for Y* is specified as
VC = α0 + K-1 [ αK + ½ βKK

K-1 + βKL. PL + βKE .PE ]
Y

+ PL ( αL + ½βLL .PL + βLE .PE + βLY .Y )
+ PE ( αE + ½βEE .PE + βEY .Y ) + Y( αY + ½ βYY .Y ) ………. (4)
K-1 is the capital stock at the beginning of the year which implies that a firm makes output
decisions constrained by the capital stock at the beginning of the year. Capacity output (Y*)
for a given level of quasi-fixed factor is defined as that level of output which minimizes
STC. So, the optimal capacity output level, for a given level of quasi-fixed factors, is
defined as that level of output which minimizes STC. So, at the optimal capacity output
level, the envelop theorem implies that the following relation must exist.
∂STC/∂K = ∂VC/∂K + PK

=

0

---------------------

(5)

In estimating Y*, we differentiate VC equation (4) w.r.t K-1 and substitute expression in
equation (5)
Y* =
(6)

– βKK. K-1
( αK + βKL. PL + βKE .PE + PK )

………….

The estimates of CU can be obtained by combining equation (6) and (1).

Description of data and variables:

3

Similar functional form has been previously estimated by Denny et al (1981). The variable cost function
is based on the assumption that some input like capital cannot be adjusted to their equilibrium level.
Therefore, the firm minimizes variable cost given the output and the quasi fixed inputs.
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A difficulty faced by researchers in conducting studies on capacity utilization in Indian
industries is that available official data on Industrial capacities are quite unsatisfactory. The
present study is based on industry-level time series data taken from several issues of Annual
Survey of Industries, NAS and Economic Survey , Statistical abstracts (various issues), RBI
bulletin etc. covering a period of 29 years commencing from 1979-80 to 2007-08. Selection
of time period is largely guided by availability of data. 4
Output and Variable cost:
Details of methods employed for the measurement of variables are given in Appendix.
Output is measured as gross output ( Appendix-A1) produced by manufactures suitably deflated
by WIP index for manufactured product (base 1981 – 82 = 100) to offset the influence of
price changes variable cost is sum of the expenditure on variable inputs (VC = PL .L+
PE.E).
Labor and price of labor:
The total number of persons engaged in the pharmaceutical sector is used as a measure of
labor inputs. Price of labor (PL) is the total emolument divided by number of laborers which
includes both production and non-production workers (Goldar & others, 2004) 5
Energy and Price energy:
Deflated cost of fuel (Appendix-A2) has been taken as measure of energy inputs. Due to
unavailability of data regarding periodic price series of energy in India, some
approximations become necessary. We have taken weighted aggregative average price
index of fuel (considering coal, petroleum and electricity price index, suitably weighted,
from statistical abstract) as proxy price of energy. 6
Capital stock and price of capital:
Deflated gross fixed capital stock at 1981-82 prices is taken as the measure of capital input.
The estimates are based on perpetual inventory method. (Appendix-A3) Rental price of capital is

4

Until 1988 – 89, the classification of industries followed in ASI was based on the National Industrial
classification 1970 (NIC 1970). The switch to the NIC-1987 from 1989-90 and also switch to NIC1998
requires some matching. For price correction of variable, wholesale price indices taken from official
publication of CMIE have been used to construct deflators.
5

One serious limitation of this assumption is that this does not take into account variations in quality and
the composition of labor force.

6

To compute the price of energy inputs, some studies have aggregated quantities of different energy
inputs using some conversion factors (say British Thermal units or coal replacement etc.) and then take
the ratio of expenditure on energy to the aggregate quantity of energy. This method is criticized because it
assumes different types of energy inputs to be perfect substitutes.

PAGE

214

2011 JOURNAL OF EMERGING KNOWLEDGE ON EMERGING MARKETS ● WWW .ICAINSTITUTE.ORG

Published by DigitalCommons@Kennesaw State University, 2011

9

Journal of Emerging Knowledge on Emerging Markets, Vol. 3 [2011], Art. 13
MEASURING CAPACITY UTILIZATION AND EVALUATING THE IMPACT OF LIBERALIZATION ON
CAPACITY UTILIZATION OF THE INDIAN DRUG AND PHARMACEUTICAL INDUSTRY

assumed to be the price of capital (PK) which can be obtained from the ratio of interest paid
to capital invested.
Empirical Estimation of Capacity and its Utilization
This section presents the results of a multiple regression analysis applied to measure
capacity output. The variable cost equation as shown in equation (4) above has been
estimated by the ordinary least square method (OLS). In Tables 1 and 2, we reproduce
measure of capacity utilization by economic measure for Indian pharma industry at
aggregate level during pre and post-reform period respectively. From the estimate, we get a
broad picture regarding variation in CU ratios.
Table – 1
Trend in utilization of capacity of Indian Pharmaceutical industry at aggregate level.
(Pre-reform period -1979-80 to 1991-92)
Year

Economic
capacity
output
(Y*)(Cr. Rs)

Actual
output
(Y)

Economic
CU = Y/Y*

Growth in
capacity
(%)

Growth in
output (%)

(Cr. Rs)

1979-80

3142

2397

0.7629

-

-

80-81

3293

2803

0.8512

4.81

16.94

81-82

3724

3361

0.9025

13.09

19.91

82-83

3899

3649

0.9359

4.70

8.57

83-84

3988

4069

1.0203

2.28

11.51

84-85

4331

4312

0.9956

8.60

5.97

85-86

4619

4175

0.9039

6.65

-3.18

86-87

5064

5274

1.0415

9.63

26.32

87-88

5312

5192

0.9774

4.90

-1.55

88-89

5277

5421

1.0273

-0.66

4.41

89-90

5598

5643

1.0080

6.08

4.10

90-91

5989

5879

0.9816

6.98

4.18

91-92

6739

5982

0.8877

12.52

1.75

0.9458

6.63

8.24

Average

Source: Created by author from Annual Survey of Industries (several issues).
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Table – 2
Trend in utilization of capacity of Indian Pharmaceutical industry at aggregate level.
(Post-reform period-1991-92 to 2007-08)
Year

Economic
capacity output
(Y*)(Cr. Rs)

Actual
output (Y)

Economic Cu
= Y/Y*

Growth in
capacity
(%)

Growth in
output (%)

91-92

6739

5982

0.8877

-

-

92-93

7058

6236

0.8835

4.73

4.25

93-94

6172

6425

1.0410

-12.55

3.03

94-95

8956

9293

1.0376

45.11

44.64

95-96

9562

9142

0.9561

6.77

-1.62

96-97

11438

10248

0.8960

19.62

12.10

97-98

11726

10783

0.9196

2.52

5.22

98-99

12452

12846

1.0316

6.19

19.13

99-00

12789

12874

1.0066

2.71

0.22

00-01

13589

13985

1.0291

6.26

8.63

01-02

14578

14027

0.9622

7.28

0.30

02-03

14129

11433

0.8092

-3.08

-18.49

03-04

6739

5982

0.8877

-52.30

9.76

04-05

14785

12549

0.8488

119.39

2.75

05-06

14524

12894

0.8878

-1.77

10.57

06-07

14623

14257

0.9750

0.68

5.93

07-08

15743

15102

0.9593

7.66

4.25

0.9423

9.95

6.92

average

(Cr. Rs)

Source: Created by author from Annual Survey of Industries (several issues).
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From the analysis, we notice a number of important findings.
First, it has been noticed that if capacity output is taken to be the economic capacity
derived from optimization process, the CU ratio could exceed one in more general cases
indicating that production is to the right of the minimum point of short-run average total
cost curve inducing cost-reducing net-investment. The implication of economic CU
exceeding unity is that when there is a sudden increase in demand and immediate rise in
price may not be feasible and in the short run, it might be necessary to operate at a point
beyond the cost minimizing or profit maximizing point. This may so happen when firms
attempt to maintain their reputation or market share, bear some of the cost burdens in the
short run and oblige their customers through an increased supply of goods at unchanged
prices. Our study shows that some of the years, both in pre and post- reform periods, have
shown CU exceeding one. This finding induces us to conclude that the firms could have
reduced their production cost by moving to the minimum point of short run average cost
curve.
Second, economic measure of CU shows much more variation which is apparent from our
study that the economic CU index ranges from about 0.76 to 1.04. Standard deviation of
economic CU during pre and post-reform period are 0.081 and 0.072 respectively which
signifies greater variation of economic CU in both segments of time period.
Third, the estimate in table-1 and 2 shows that industry’s average economic CU slightly
declined from 0.9458 to 0.9423 during post-reform period but reverse trends have been
noticed in the average growth rate of capacity. During pre-reform period, capacity
expansion was poor probably due to licensing restriction and demand grows at very rapid
pace at that period but abolition of license raj during post-reform period paved the way for
expansion of capacity abruptly. The growth rate in demand shows a declining trend during
post-reform period as compared to pre-reform period.
Fourth, it is important to note that the significant improvement in the rate of capacity
utilization of the industry was accomplished up to mid-90s despite substantial growth in its
economic capacity indicating more efficient use of capital and other resources in this
particular industry.
Impact of Liberalization on Economic CU
In investigating the issue of whether there exists any positive or negative impact of
economic reforms on capacity utilization more precisely, we use a piecewise linear
regression equation (popularly known as Spline function) where it is assumed that capacity
utilization increases linearly with the passage of time until the threshold time period ( t0 ).
[Here, t0=1990-91 being last year of pre-reform period after which post-liberalization era
begins] after which also it changes linearly with the passage of time but at a much steeper
rate. Therefore, we have a piecewise linear regression consisting of two linear pieces or
segments. The CU function changes it slope at the threshold value (t0=12). Given the data
on capacity utilization, time period and the value of threshold level, the technique of
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dummy variables can be used to estimate the slopes of the two segments of the piecewise
linear regression. The piecewise linear regression equation is as follows:
ln.Yt = α + βt + β′(t – t0) Dt
Result of the Regression Equation is as follows:
ln .Yt = -0.1470 + 0.01215t – 0.0174Dt
(-3.46)

(2.59)

(-2.64)

R2 = 0.22
Figures in the parenthesis are usually t values. Here β gives the slope of the regression line
in pre-reform period which is positive and significant at 5% level. This implies that growth
in capacity utilization shows positive trend immediately before liberalization starts.
But as co-efficient of the difference between two time period is significant at 5% level and
negative (coefficient being –0.0174), conclusive inference can be drawn in that
liberalization has its significant negative impact on capacity utilization during post-reforms
period.

PAGE

218

2011 JOURNAL OF EMERGING KNOWLEDGE ON EMERGING MARKETS ● WWW .ICAINSTITUTE.ORG

Published by DigitalCommons@Kennesaw State University, 2011

13

Journal of Emerging Knowledge on Emerging Markets, Vol. 3 [2011], Art. 13
MEASURING CAPACITY UTILIZATION AND EVALUATING THE IMPACT OF LIBERALIZATION ON
CAPACITY UTILIZATION OF THE INDIAN DRUG AND PHARMACEUTICAL INDUSTRY

Table – 3
Trend in Growth rate of Capacity utilization (1979-80 to 2007-08)
Pre- reform period(1979-80 to 1991-92)

Pre- reform period(1991-92 to 2007-08)

Year

Growth rate (%)

Year

Growth rate (%)

1979-80

-

91-92

-9.57

80-81

11.57

92-93

-0.47

81-82

6.03

93-94

17.83

82-83

3.70

94-95

-0.33

83-84

9.02

95-96

-7.85

84-85

-2.42

96-97

-6.29

85-86

-9.21

97-98

2.63

86-87

15.22

98-99

12.18

87-88

-6.15

99-00

-2.42

88-89

5.11

00-01

2.24

89-90

-1.88

01-02

-6.50

90-91

-2.62

02-03

-15.90

91-92

-9.57

03-04

9.70

04-05

-4.38

05-06

4.59

06-07

9.82

07-08

-1.61

Average

1.57

0.83

Source: Created by author from Annual Survey of Industries (several issues).

It is visible from the estimated average growth rate in capacity utilization as shown in Table
– 3 that there is a significant drop in average growth rate of capacity utilization from 1.57%
in pre-reform period to 0.83% in post- reform period.
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Factors influencing capacity utilization
It is well recognized that utilization of capacity reflects the influences of markets supply
and demand conditions, government policies, the degree of monopolization within an
industry and the attitude of the managers of the firms in under developed countries (S. Paul,
1974). Demand deficit, labor problem, transport bottlenecks, failure in power supply,
mechanical/ maintenance trouble, strikes etc. are major cause responsible for underutilization of Industrial capacity in India. Apart from the above mentioned factors, industry
characteristics like demand pressure, capital intensity, market concentration, scale of
operation, etc. and policy variables influence capacity utilization rates of an industry. Paul
(1974) found that industry characteristics explaining 40% of inter-industry variation in CU
rates and policy variables explaining 32% of the inter-industry variation comprise nearly
72% of the total inter-industry variations in CU.
In this section, we have attempted to explain the nature of relationship between capacity
utilization and different industrial characteristics (excluding other explanatory policy
variables like import substitution, effective rate of protection etc. due to unavailability of
reliable, comparable data) based on industry level and company wise time series data in the
context of Indian pharmaceutical Industry.
We analyze econometrically the effect of demand pressure, capital intensity, market
concentration and scale of operation on capacity utilization. It employs multiple regression
analysis technique (OLS) considering all explanatory variables in the same equation.
Similar attempts were made earlier in the study of S. Paul (1974), Srinivasan (1992) and
Goldar and Renganathan (1991).
Independent variables considered in the present study are demand pressure, capital
intensity, market concentration and scale of operation. These explanatory variables can be
interpreted as under:
Demand Pressure (GO): Demand Pressure is measured by growth rate of production over
the time period.
A positive relationship is expected between demand pressure and capacity utilization on the
assumption that high demand pressure will enable the firms within a particular industry to
make better utilization of productive capacity.
Capital Intensity (K/L): Capital intensity is expressed as the productive capital used per
person engaged. It is obtained by dividing productive capital by number of persons
engaged.
A positive relationship between capacity utilization and capital intensity is expected
because high capital intensive firms of an industry enjoy better economies of scale inducing
higher utilization rates.
Market Concentration (CONR): Market concentration is defined as the percentage of the
sale value accounted for by the top 4 companies in the total sales of the industry. Top 4
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companies have been chosen from CMIE data book in accordance with highest sales
volume.
Greater efficiency of some firms within the industry ensures better market concentration. A
few firms capture a larger portion of market share due to their excellent efficiency resulting
in increase in market concentration. Gradually, inefficient firms are wiped out of
competition as a result of generating poor quality and charging high prices of products (due
to increase in cost of production). Consequently, efficient firms expand their capacity as
well as utilization rates to cope-up with the growing market demand thereby expecting a
positive relationship between capacity utilization and market concentration.
Scale of operation (MS): Scale of operation is defined as the value of its sale as a
percentage of the total sales of the manufacturing industry.
Capacity utilization can be influenced by the scale of operation of individual firms. As the
scale of operation increases, there may be fewer bottlenecks and the lumpiness of the
individual machine is more easily balanced, thereby increasing the average CU (Lecraw,
D.J, P-145). Therefore, one would expect a positive relationship between CU and scale of
operation.
In order to examine the effect of various forces (that affect CU) on capacity utilization, we
estimate a linear multiple regression equation for all firms taken together using industry
level and company wise time series data over a period of 29years. The single equation
model with CU as dependent variables and demand pressure (GO), capital intensity (K/L),
market concentration (CONR), scale of operation (MC) along with time variable (T) as
explanatory variables is depicted as under :U = α + β1GO + β2 (K/L) + β3 (CONR) + β4 (MS) + β5 T
Where GO = Growth in production.
K/L = Capital intensity.
CONR = Concentration ratio.
MS = Market share representing scale of operation.
T =Time variable ,U = capacity utilization rate.
The regression equation is estimated by ordinary least square (OLS) technique. CU is
regressed separately on each independent valuable in different equations and then all
explanatory variables are regressed in a single equation.
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Table – 4
Regression Result for Pharmaceutical Sector relating CU to GO, K/L, CONR, MS and T.
Dependent Variable: Capacity Utilization
Equation

Intercept
Term

GO

K/L

CONR

MS

T

R2

1.

-0.11

0.6277

4.794

1.415

0.8041

-0.064

0.7426

(-0.197)*

(2.627)

(1.96)

(1.94)

(0.287)

(-2.82)

-

0.6054

4.55

1.30

0.44

-0.0632

(3.06)

(2.26)

(2.82)

(0.222)

(-3.01)

-0.0072

0.5928

4.62

1.41

-

-0.065

(-0.018)

(3.06)

(2.07)

(2.04)

1.27

-

-

-

2.

3.

4.

(3.42)
5.

6.

7.

(-1.94)

-

-0.0597

(2.46)

(1.43)

0.581

-

1.57

1.23

-2.95

-0.03

(3.39)

(2.66)

(-0.92)

(-1.38)

-

1.13

-2.93

-0.0235

(2.41)

(-0.97)

(-1.78)

-

-

-0.0232

-

-

(6.98)
0.3789

0.881

-

-

0.41

(19.15)

(1.96)

-

0.6033

0.4888

0.46

0.3365

(-0.97)
1.088

-

(2.36)

0.9417

0.3772

(-2.43)

(1.9)

(0.786)
10

(-0.87)

(6.53)

0.9172

9.

-0.026

3.633

(1.19)
8.

-2.73

0.5505

0.69

0.7396

(-3.04)

0.7839

(0.91)

-

0.7412

-

-0.0127

0.4144

(-1.78)
-

-0.0264

0.5134

(-3.24)

Source: Created by author from Annual Survey of Industries & CMIE (several
issues).
* t values are given in the parenthesis below
GO =Growth in output indicating demand pressure
K/L = Capital intensity
CONR = Market concentration ratio
MS= Market Share representing scale of operation
T= Time variable
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Table 4 above presents the estimated regression equations. We find a significant positive
relationship between CU and demand pressure variable which supports our hypothesis. The
coefficient of demand pressure variable is positive and is statistically significant in all
equations at 0.05 level. The major implication of this result is that as the growth rate of
production indicating demand pressure increases, pressure is expected to come upon the
firms within the industry that have idle capacities to enhance their utilization rates. This
suggests that with growing demand for products, pharmaceutical industry has been
gradually moving towards fuller utilization of capacity.
The regression coefficient of capital intensity variable is all positive. The regression
coefficient is statistically significant at 0.05 level in four equations, one at 0.10 level and
another at 0.20 level. It indicates that pharma sector with relatively more capital intensive
units tend to have higher rates of capacity utilization. Capital intensity is generally
considered to be the proxy for technology level. With the relaxation of import restrictions
due to reform process, firms have resorted to more foreign capital – intensive technologies
inviting huge opportunity cost of unused capital. The result suggests that capacity
utilization rate is more in high capital intensive firms because unless these type of firms
operate at higher utilization rate, they cannot recover the higher cost of capital.
The estimated coefficient of market concentration variable indicates a positive relationship
between market concentration and CU as coefficient in all equations are positive and
statistically significant at 0.05 and 0.10 level. The result implies that increase in
concentration ratio leads to higher utilization of capacity.
This shows that higher seller concentration creates barriers on entry of new firms in the
industry which assists concentrated firms to utilize its capacity at its fullest possible level
thereby ensuring most effective utilization of scare capital resources.
Our regression result reveals that scale of operation variable represented by market share is
found to be confusing and statistically insignificant. This reveals that firms with sizable
portion of market share do not have significant stimulation regarding utilization of its
installed capacity. The result is contrary to our hypothesis.
The explanation for not finding any significant relationship between CU and market share
lies in the fact that there has not much change in market share of this sector over our study
period, especially during 90’s.

Summary and findings
As discussed earlier, India has undertaken various reform programs since 1991 in order to
make the economy competitive and to meet the global challengers. This paper tries to
examine the trends in capacity utilization in the Indian pharmaceutical sector during pre and
post-reform period. The major findings of the present study may be summarized below.
First, there was a slight decrease in average capacity utilization rate in post-reform period as
compared to pre-reform period. Secondly, annual average growth rate of capacity output
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reveals increasing trend in growth rate at a much steeper rate but actual output shows
declining trend . Therefore, the trend in capacity expansion reflects that capacity expanded
more rapidly in post-reform period than in pre-reform period. Thirdly, there is a sharp
decline in the average annual growth rate of capacity utilization during the post-reform
period in comparison with pre-reform period. Fourth, the estimates obtained indicate that
the liberalization process is found to have a significant adverse impact on capacity
utilization since there is a fall in average growth rate of capacity utilization during the postreform period. Fifth, it is obvious from our estimate that utilization rate of capacity fell
gradually after 1995-96. Removal of industrial licensing restriction might have encouraged
the entrepreneurs to invest more and expand their plant capacity. Actual output being an
indicator of public demand was expanding gradually up to first half of 90s and thereafter
demand did not expand as much as increase of capacity. Sixth, the high correlation
observed, in the sector, between the actual and capacity output ( r=0.97) suggests that a
substantial part of capacity could have been kept unutilized by the firms within the industry
to cope up with the unforeseen excessive demand shock coming from customers' front.
From our regression analysis, it is evident that there exists a significant positive relationship
between CU and the explanatory of variables such as demand pressure (GO) capital
intensity (K/L) and market concentration (CONR). Although scale of operation variable
reflected by sizable portion of market share was expected to exhibit a positive relationship,
the result obtained from our analysis is contradictory as well as unsatisfactory. With regard
to the “why’s” of what is revealed from our empirical result, it happens probably due to
limitation and inadequacies of data. The present study lends strong support to earlier works
conducted by Paul. S (1974) Goldar and Renganathan (1991), Srinivasan (1992).
In a liberalized regime, abolition of licensing rule encouraging new entrants, and at the
same time, growing demand inducing existing firms to expand and utilize its capacity to the
fullest possible, larger firms having greater access regarding import of capital goods
coupled with domestic capital goods inducing higher capital intensity contributed towards
favorable impact on CU.
But there are some important lessons that can be learnt from our analysis in that high
demand pressure, high capital intensity and high market concentration leading higher CU
may have adverse impact on scare resources, employment and distribution system.
In a nut shell, the empirical results presented in this study leave wider scope for further
improvement and refinement. It is suggested that while making policy decisions on the
basis of aggregate, the consideration of intra-sectoral analysis may be attempted in order to
have more valuable results because generalization based on aggregative analysis sometimes
fails to pave the way for improved decision making.
In conclusion, as far as India’s pharmaceutical industry is concerned, various options are
possible in the WTO regime. These are to: (a) manufacture of patented generic drugs, (b)
produce patented drugs under compulsory licensing or cross licensing, (c) invest in R&D to
engage in new product development, (d) produce patented and other drugs on contract

PAGE

224

2011 JOURNAL OF EMERGING KNOWLEDGE ON EMERGING MARKETS ● WWW .ICAINSTITUTE.ORG

Published by DigitalCommons@Kennesaw State University, 2011

19

Journal of Emerging Knowledge on Emerging Markets, Vol. 3 [2011], Art. 13
MEASURING CAPACITY UTILIZATION AND EVALUATING THE IMPACT OF LIBERALIZATION ON
CAPACITY UTILIZATION OF THE INDIAN DRUG AND PHARMACEUTICAL INDUSTRY

basis, (e) explore the possibilities of new drug delivery mechanisms and alternative use of
existing drugs, and (f) collaborate with multinationals to engage in R&D, clinical trials,
product development or marketing the patented product on a contract basis and so on.
Besides these strategies, India’s strength lies in process development skills. This expertise
utilized within the WTO framework with emphasis on quality standards will provide India a
competitive advantage over other Asian countries.
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APPENDIX:
Appendix-A1: In industry level analysis, it is a recent practice to utilize gross output rather
than value-added as a measure of product at the industry level. Jorgenson (1988) has shown
that in a three input production framework, the contribution of intermediate input is the
significant source of output growth in US economy. Intermediate input in our study consists
of energy only. The yearly fuel consumed is taken as measure of energy input.
Appendix-A2: Energy Inputs: Industry level time series data on cost of fuel of Indian
Drug & pharmaceutical sector have been deflated by suitable deflator (base 1981-82 = 100)
to get real energy inputs. An input output table provides the purchase made by
manufacturing industry from input output sectors. These transactions are used as the basis
to construct weight and then weighted average of price index of different sectors is taken.
Taking into consideration 115 sector input – output table (1998 – 99) prepared by CSO, the
energy deflator is formed as a weighted average of price indices for various input – output
sectors which considers the expenses incurred by manufacturing industries on coal,
petroleum products and electricity as given in I-O table for 1998 – 99. The WIP indices
(based 1981 – 82) of Coal, Petroleum and Electricity have been used for these three
categories of energy inputs. The columns in the absorption matrix for 66 sectors belonging
to manufacturing (33 – 98) have been added together and the sum so obtained is the price of
energy made by the manufacturing industries from various sectors. The column for the
relevant sector in the absorption matrix provides the weights used.
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AppendixA3: Capital Stock: The procedure for the arriving at capital stock series is
depicted as follows :
First, an implicit deflator for capital stock is formed on Net Fixed Capital Stock( NFCS) at
current and constant prices given in NAS. The base is shifted to 1981-82 to be consistent
with the price of inputs and output.
Second, an estimate of net fixed capital stock (NFCS) for the registered manufacturing
sector for 1970-71 (benchmark) is taken from National Accounts Statistics. It is multiplied
by a gross-net factor to get an estimate of gross fixed capital stock (GFCS) for the year
1970-71. The rate of gross to net fixed asset available from RBI bulletin was 1.86 in 197071 for medium and large public Ltd. companies. Therefore, the NFCS for the registered
manufacturing for the benchmark year (1970-71) as reported in NAS is multiplied by 1.86
to get an estimate of GFCS which is deflated by implicit deflator at 1981-82 price to get it
in real figure. In order to obtain benchmark estimate of gross real fixed capital stock made
for registered manufacturing, it is distributed among various two digit industries (in our
study, pharmaceutical industry) in proportion of its fixed capital stock reported in ASI,
(1970-71).
Third, from ASI data, gross investment in fixed capital in pharmaceutical industry is
computed for each year by subtracting the book value of fixed capital in previous year from
that in the current year and adding to that figure the reported depreciation fixed asset in
current year. (Symbolically, It = (βt - βt-1 + Dt ) / Pt) and subsequently it is deflated by the
implicit deflator to get real gross investment.
Fourth, the post benchmark real gross fixed capital stock is arrived at by the following
procedure. Real gross fixed capital stock (t) = real gross fixed capital stock (t – 1) + real
gross investment (t). The annual rate of discarding of capital stock (Dst) is assumed to be
zero due to difficulty in obtaining data regarding Dst.
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